Literature DB >> 2578878

Direct and indirect effects of interferon on in vivo murine tumor cell growth.

K Uno, S Shimizu, M Ido, K Naito, K Inaba, T Oku, T Kishida, S Muramatsu.   

Abstract

We cloned two sublines (S1 and R1) of murine Meth A fibrosarcoma cells with respect to their sensitivity to a murine alpha/beta-interferon (IFN) preparation. The growth of S1 cells was suppressed and that of R1 cells was hardly affected by IFN in vitro. This was also the case with cells enclosed in cell-impermeable diffusion chambers in peritoneal cavities. Nevertheless, IFN suppressed the growth of not only S1 cells but also R1 cells in mice inoculated i.p. with these cells, and the survival rates of both S1 cell recipients and R1 cell recipients were markedly improved. S1 cells were observed microscopically to be injured by the direct effect of IFN in vitro and in vivo, but R1 cells in in vitro culture with IFN and those surviving in vivo in the presence of IFN appeared to proliferate well. In the peritoneal cavity of R1 recipients treated daily with IFN, the recruitment of macrophages was enhanced in comparison with untreated R1 recipients. Adherent peritoneal exudate cells obtained from IFN-treated, R1-bearing mice were highly suppressive for the in vitro growth of not only R1 cells but also allogeneic and human cells. The role of macrophages in the indirect effect of IFN on tumor cell growth is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578878

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Synthesis of gelatin microspheres containing interferon.

Authors:  Y Tabata; Y Ikada
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

2.  Protein precoating of polylactide microspheres containing a lipophilic immunopotentiator for enhancement of macrophage phagocytosis and activation.

Authors:  Y Tabata; Y Ikada
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

3.  Induction of antitumor activity in macrophages by mycoplasmas in concert with interferon.

Authors:  K Uno; M Takema; S Hidaka; R Tanaka; T Konishi; T Kato; S Nakamura; S Muramatsu
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.

Authors:  T Itoh; Y Sakata; Y Yoshida; K Tsushima; H Suzuki; S Saitoh; Y Tamura; H Ogasawara; N Sugimoto; H Takemori
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.

Authors:  M Zöller
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

6.  Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice.

Authors:  C M Fleischmann; G J Stanton; W R Fleischmann
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

7.  Antitumor and antimetastatic activities of human recombinant interferon alpha A/D.

Authors:  J Nishimura; K Mitsui; T Ishikawa; Y Tanaka; R Yamamoto; Y Suhara; H Ishitsuka
Journal:  Clin Exp Metastasis       Date:  1985 Oct-Dec       Impact factor: 5.150

8.  Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.

Authors:  Yoshio Katamura; Hiroshi Aikata; Shintaro Takaki; Takahiro Azakami; Tomokazu Kawaoka; Koji Waki; Akira Hiramatsu; Yoshiiku Kawakami; Shoichi Takahashi; Masahiro Kenjo; Naoyuki Toyota; Katsuhide Ito; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2009-03-28       Impact factor: 7.527

9.  Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma.

Authors:  M Sakurai; M Iigo; T Tamura; A Otsu; Y Sasaki; H Nakano; K Nakagawa; K Minato; Y Ohe; N Saijo
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.

Authors:  Satoru Hagiwara; Masatoshi Kudo; Kazuomi Ueshima; Hobyung Chung; Mami Yamaguchi; Masahiro Takita; Seiji Haji; Masatomo Kimura; Tokuzo Arao; Kazuto Nishio; Ah-Mee Park; Hiroshi Munakata
Journal:  J Gastroenterol       Date:  2010-08-04       Impact factor: 6.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.